Study Title
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participants with cancer harboring BRAF alterations
Protocol ID
FORTE
Condition/s
Cancer habouring BRAF alterations
Diagnosis Stage
Locally advanced/metastatic
Recurrent/Refractory
Recurrent/Refractory
Location
NSW
Sponsor
Fore Biotherapeutics
Links
Trial Status
Open
Sites
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
Greater than or equal to 10 years
International registry ID's
NCT05503797
| Study Title | A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394 an inhibitor of BRAF Class 1 and Class 2 alterations in participants with cancer harboring BRAF alterations |
|---|---|
| Protocol ID | FORTE |
| Disease (Sub Disease) | Cancer habouring BRAF alterations |
| Diagnosis Stage | Locally advanced/metastatic Recurrent/Refractory |
| Location | NSW |
| Sponsor | Fore Biotherapeutics/ |
| Links | https://www.clinicaltrials.gov/study/NCT05503797 |
| Trial Status | Open |
| Trial Open Date | 01/03/2025 |
| Sites | Sydney Children's Hospital/ |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | Greater than or equal to 10 years |
| International registry ID's | NCT05503797 |